186 related articles for article (PubMed ID: 34305008)
1. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
2. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
3. How the COVID-19 pandemic changed cellular therapy at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital.
Tanhehco YC; Schwartz J
Transfusion; 2020 Sep; 60(9):1905-1909. PubMed ID: 32583465
[TBL] [Abstract][Full Text] [Related]
4. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
Dinh A; Stroncek DF
Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
[TBL] [Abstract][Full Text] [Related]
5. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
6. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
7. Management of externally manufactured cell therapy products: the Mayo Clinic approach.
Wiltshire TD; Deeds MC; Radel DJ; Bornschlegl AM; Schmidt CS; Thebiay JM; Pelleymounter LL; Jacob EK; Stubbs JR; Gastineau DA; Dietz AB
Cytotherapy; 2022 Jan; 24(1):19-26. PubMed ID: 34980364
[TBL] [Abstract][Full Text] [Related]
8. Expanding the reach of commercial cell therapies requires changes at medical centers.
Stroncek DF; Zhang N; Ren J; Somerville R; Dinh A
J Transl Med; 2024 Feb; 22(1):181. PubMed ID: 38374090
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
Mukherjee S; Reddy O; Panch S; Stroncek D
Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
[TBL] [Abstract][Full Text] [Related]
10. Variations in novel cellular therapy products manufacturing.
Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
[TBL] [Abstract][Full Text] [Related]
11. The quest for quality blood banking program in the new millennium the American way.
Kim DU
Int J Hematol; 2002 Aug; 76 Suppl 2():258-62. PubMed ID: 12430934
[TBL] [Abstract][Full Text] [Related]
12. Establishing a Satellite Transfusion Service Within an Academic Medical Center.
Murphy CH; Lim AY; Chua L; Shan H; Goodnough LT; Virk MS
Am J Clin Pathol; 2020 May; 153(6):842-849. PubMed ID: 32157269
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
15. The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.
McKenna DH; Kadidlo DM; Miller JS; Orchard PJ; Wagner JE; McCullough J
Transfus Med Rev; 2005 Jul; 19(3):217-28. PubMed ID: 16010652
[TBL] [Abstract][Full Text] [Related]
16. Cellular Therapies Clinical Research Roadmap: lessons learned on how to move a cellular therapy into a clinical trial.
Ouseph S; Tappitake D; Armant M; Wesselschmidt R; Derecho I; Draxler R; Wood D; Centanni JM
Cytotherapy; 2015 Apr; 17(4):339-43. PubMed ID: 25484311
[TBL] [Abstract][Full Text] [Related]
17. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
Warkentin PI;
Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
[TBL] [Abstract][Full Text] [Related]
18. How do we… direct a transfusion service/blood bank with limited laboratory staff.
Lu W; Bakhtary S; Oliver L; Stephens L; Tanhehco Y; O'Brien K
Transfusion; 2023 Nov; 63(11):2023-2031. PubMed ID: 37642158
[TBL] [Abstract][Full Text] [Related]
19. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
20. Six Sigma: not for the faint of heart.
Benedetto AR
Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
